美国产前破伤风、白喉、无细胞百日咳疫苗接种预防婴儿百日咳的效果
该研究为全国性队列研究,分析2010-2014年分娩的孕妇及其婴儿的商业保险理赔数据,比较产前接种Tdap与未接种孕妇的婴儿百日咳发生率。结果显示,产前接种Tdap的婴儿百日咳发生率较未接种孕妇的婴儿低43%(HR=0.57,95%CI=0.35,0.92),且效果在妊娠晚期接种时一致;妊娠<27周接种未见发生率降低(HR=1.10,95%CI=0.54,2.25)。结论不支持改变当前推荐的孕期Tdap接种时机。
要点
- 产前接种Tdap的婴儿百日咳发生率较未接种孕妇的婴儿低43%(HR=0.57,95%CI=0.35,0.92)。
- 妊娠晚期接种Tdap的婴儿百日咳发生率也较低。
- 妊娠<27周接种Tdap的婴儿未见百日咳发生率降低(HR=1.10,95%CI=0.54,2.25)。
核心结论
- 产前接种Tdap的婴儿百日咳发生率约为未接种孕妇婴儿的一半。
- 结果不支持改变当前推荐的孕期Tdap接种时机。
研究设计与样本
- 全国性队列研究,纳入2010-2014年分娩的孕妇及其婴儿,共675,167对母婴。
- 分析2016-2017年商业保险理赔数据,识别孕妇Tdap接种及婴儿至18月龄的百日咳住院和门诊就诊。
主要发现
- 产前接种Tdap的婴儿百日咳发生率较未接种孕妇(未接受产前或产后Tdap)的婴儿低43%(HR=0.57,95%CI=0.35,0.92)。
- 仅住院百日咳的HR=0.32(95%CI=0.11,0.91)。
- 妊娠晚期接种Tdap的婴儿百日咳发生率也较低。
- 妊娠<27周接种Tdap的婴儿未见百日咳发生率降低(HR=1.10,95%CI=0.54,2.25)。
临床怎么用
- 原文结论未据此给出推荐,仅指出结果不支持改变当前推荐的孕期Tdap接种时机。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: It is recommended that all pregnant women in the U.S. receive tetanus, diphtheria, acellular pertussis (Tdap) immunization to prevent infant pertussis. This study's objective was to examine the clinical effectiveness of prenatal Tdap, and whether effectiveness varies by gestational age at immunization. METHODS: A nationwide cohort study of pregnant women with deliveries in 2010-2014 and their infants was performed. Commercial insurance claims data were analyzed in 2016-2017 to identify Tdap receipt by the pregnant women, and hospitalizations and outpatient visits for pertussis in their infants until the infants reached 18 months of age. Pertussis occurrence was compared between infants of mothers who received prenatal Tdap (overall and stratified by gestational age at administration) and infants of unvaccinated mothers. RESULTS: There were 675,167 mother-infant pairs in the cohort. Among infants whose mothers received prenatal Tdap, the rate of pertussis was 43% lower (hazard ratio=0.57, 95% CI=0.35, 0.92) than infants whose mothers did not receive prenatal or postpartum Tdap; this reduction was consistent across pertussis definitions (hazard ratio for inpatient-only pertussis=0.32, 95% CI=0.11, 0.91). Pertussis rates were also lower for infants whose mothers received Tdap during the third trimester. Infants whose mothers received Tdap at <27 weeks of gestation did not experience reductions in pertussis rates (hazard ratio for pertussis=1.10, 95% CI=0.54, 2.25). CONCLUSIONS: Infants of mothers who received prenatal Tdap experienced half the rate of pertussis as compared with infants of unimmunized mothers. These results do not provide evidence to support changing the currently recommended timing of Tdap administration in pregnancy.
引用
- Becker-Dreps S, Butler AM, McGrath LJ, et al. Effectiveness of Prenatal Tetanus, Diphtheria, Acellular Pertussis Vaccination in the Prevention of Infant Pertussis in the U.S. Am J Prev Med. 2018. PMID: 29910115. doi:10.1016/j.amepre.2018.04.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。